Clinical Research Studies

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Multiple Sclerosis
• Age: Between 18 years - 99 years
• Gender: Male or Female

• Other Inclusion Criteria:
  

  1. Signed informed consent
  2. Have a diagnosis of MS
  3. Newly treated with ocrelizumab (within 30 days before baseline visit [study entry]) according to the local label irrespective of the reason for starting ocrelizumab (ocrelizumab cohort)
  OR
  4. Newly treated with one of the following 6 approved MS DMTs: alemtuzumab, cladribine, dimethyl fumarate, fingolimod, natalizumab, or teriflunomide according to the local label irrespective of the reason for starting a new MS DMT (internal comparator cohort)

  
  

You may not be eligible for this study if the following are true:

• 1. Patients who have any prior exposure to rituximab or to any anti CD-20 therapy for MS
  2. Active participation in interventional clinical trials for MS